Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine in Sickle Cell Disease
NCT01142219Phase 3Completed
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Sep 2006
- Primary completion
- Jan 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing L-arginine with Placebo (2 arms). Primary endpoint: Tricuspid Regurgitant Jet Velocity >2.5 m/s at 6 months. Started Sep 2006; status: completed.
02
Drugs
arginine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01142219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142219.